Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RXRX
)
5.800
+0.120 (+2.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
The Dawn of Hyper-Personalization: How Generative AI is Reshaping Our Digital World
Today 22:38 EDT
The digital landscape is undergoing a profound transformation as personalized AI, particularly generative AI models, are increasingly being fine-tuned to individual preferences and histories. This...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Recursion Pharmaceuticals Earnings Preview
Today 13:05 EDT
Via
Benzinga
2 Beaten-Down Stocks With Incredible Upside Potential
August 03, 2025
Getting in on the ground floor with these companies might lead to superior returns.
Via
The Motley Fool
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
July 29, 2025
Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
July 08, 2025
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Why Recursion Pharmaceuticals Stock Got Mashed on Monday
July 28, 2025
Investors weren't cheered by news from one of the biotech's rivals.
Via
The Motley Fool
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
July 26, 2025
You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.
Via
The Motley Fool
Topics
Artificial Intelligence
Retirement
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
July 26, 2025
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
Via
Benzinga
Topics
Artificial Intelligence
ETFs
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma
July 25, 2025
AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.
Via
Benzinga
3 AI Stocks Partnered With Nvidia With Massive Growth Opportunities
July 23, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Biocomputers: The Future of Computing is Alive
July 22, 2025
In the rapidly evolving world of technology, a groundbreaking frontier is emerging that could redefine the very nature of computation: biocomputers. Unlike traditional computers built from...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Recursion Pharmaceuticals Sees Sharp Gain on AI Biotech Optimism
July 22, 2025
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) experienced a notable surge in its stock price as investor enthusiasm for artificial intelligence-driven biotechnology reached new highs. The rally comes...
Via
MarketMinute
Topics
Artificial Intelligence
Top 2 Health Care Stocks You May Want To Dump This Quarter
July 22, 2025
Via
Benzinga
History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX)
July 21, 2025
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and...
Via
MarketMinute
Topics
Artificial Intelligence
Is Recursion Pharmaceuticals Gaining or Losing Market Support?
July 21, 2025
Via
Benzinga
Why Is Recursion Pharma Stock Surging On Monday?
July 21, 2025
Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.
Via
Benzinga
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday
July 21, 2025
Via
Benzinga
Jensen Huang's Nvidia Owns 6 Stocks. Here's the Best of the Bunch.
July 12, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Initial Public Offering
Intellectual Property
10 Under-the-Radar Tech Stocks With Incredible Growth Potential
July 09, 2025
Just because it's not a household name doesn't mean it's not a magnificent investment.
Via
The Motley Fool
Topics
Artificial Intelligence
Here's Why Shares in Recursion Pharmaceuticals Surged Today
July 08, 2025
Via
The Motley Fool
Microchip Technology, Tesla, Humacyte And Other Big Stocks Moving Higher On Tuesday
July 08, 2025
Via
Benzinga
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
July 08, 2025
Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments.
Via
Benzinga
The Hottest 10 Artificial Intelligence (AI) Stocks on the Market
July 08, 2025
This group of companies reflects most of the industry's past, present, and future.
Via
The Motley Fool
Topics
Artificial Intelligence
Doctors Are Being Outpaced by AI-Powered Algorithms — Here’s What It Means for Investors
July 07, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:MSFT),(NASDAQ:ASTH),(NASDAQ:RXRX),(NASDAQ:MDAI) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Fraud
Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is...'
July 07, 2025
Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.
Via
Benzinga
Topics
Artificial Intelligence
What Analysts Are Saying About Recursion Pharmaceuticals Stock
July 03, 2025
Via
Benzinga
Is the Market Bullish or Bearish on Recursion Pharmaceuticals?
June 26, 2025
Via
Benzinga
Capital Flows Shift From Research Labs to Pharmacy Counters-A Watershed Moment for AI Health
June 17, 2025
Issued on behalf of Avant Technologies Inc. Vancouver, BC – June 17, 2025 – USA News Commentary – Momentum continues to build behind AI in healthcare, as capital finds its way to technologies capable...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts
June 16, 2025
Via
Benzinga
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?
June 16, 2025
Via
The Motley Fool
Topics
Animal Testing
Artificial Intelligence
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.